Premium
Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity
Author(s) -
Germanakis Ioannis,
Anagnostatou Nikol,
Kalmanti Maria
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21633
Subject(s) - cardiotoxicity , medicine , anthracycline , troponin , cardiology , contractility , troponin i , heart failure , brain natriuretic peptide , cancer , chemotherapy , myocardial infarction , breast cancer
Anthracycline‐related cardiotoxicity has a substantial negative impact on long‐term survivors of childhood cancer. The detection of cardiotoxicity is currently based on echocardiography or radionuclide angiography. However, as they depict only the final outcome of myocardial injury in terms of reduced heart contractility, heart specific biomarkers of myocardial destruction or dysfunction could be advantageous by allowing for an earlier detection of cardiotoxicity. In the present study, the usefulness of cardiac troponins and natriuretic peptides, the most commonly used biomarkers of myocardial destruction and ventricular dysfunction respectively, to detect and to predict the development of anthracycline cardiotoxicity has been reviewed. Pediatr Blood Cancer 2008;51:327–333. © 2008 Wiley‐Liss, Inc.